alchemab.comCrawled Oct 16, 2026
Alchemab Therapeutics announced research on AntiBERTa, a transformer neural network that reads components of antibody amino acid sequences.
Adaptive immunity represents nature’s most effective search engine: Disease protection arises through a beneficial antibody providing a selective advantage over a myriad of different antibodies.
Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics at Oxford’s BioEscalator redirected their expertise and business plans to develop COVID-19 detection methods and potential therapeutics, collaborating with nearby experts.
Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity.
20 May 2020 – Alchemab’s publication illustrating progress in understanding patients’ immune responses to COVID19 which will help inform vaccination and antibody therapeutics.
Deep sequencing of B cell receptor heavy chains from 31 COVID-19 patients in the UK revealed a stereotypical naive immune response to SARS-CoV-2 across patients. The study also observed B cell clonal expansion, possibly due to memory bystander effects.
Alchemab received a UK Biomedical Catalyst early award grant from Innovate UK to support development of an antibody therapy for Huntington’s disease. The grant supports its collaboration with Medicines Discovery Catapult.
Cambridge, UK, 15 April 2021 – Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
Alchemab Therapeutics, a biotechnology company focused on discovering and developing naturally occurring protective antibodies in neurodegeneration and oncology, appointed Douglas A. Treco, PhD as CEO. Treco will join the board and be based in Boston, Massachusetts.
Alchemab Therapeutics appointed Young T. Kwon, PhD, as Chief Financial and Operating Officer. The company focuses on discovering and developing naturally occurring protective antibodies in neurodegeneration and oncology.
The company develops therapeutics to treat and cure neurodegenerative diseases and cancer.
Donna Finch is Alchemab’s Vice President of Translational and Clinical Science and oversees target discovery and validation, and non-clinical and early clinical development.
Jake Galson is Alchemab’s Vice President of Technology where he leads the development and application of novel technologies for the company.
Jane Osbourn leads Alchemab. She previously served as Vice President of R&D at MedImmune, where she contributed to antibody phage display technology and the development of antibody therapies including HUMIRA and IMFINZI.
Kevin Lee is Chief Executive Officer of Bicycle Therapeutics and a Non-Executive Director of Mestag and NodThera Ltd. At Pfizer, Kevin held responsibility for more than 20 rare disease programs and established Pfizer’s rare disease strategy.
Alchemab uses patient samples, deep B cell sequencing and computational analysis to identify convergent protective antibody responses among people susceptible but resilient to specific diseases.
The company collaborates with experts in medicine and science to develop therapeutics.
The company lists info@alchemab.com for general inquiries.
Alchemab Therapeutics Ltd is registered in England and Wales under number 12156844 and says it protects personal data collected about website visitors and end customers.
